Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoides
Pietro Quaglino(Department of Medical Sciences), Giuseppe Lombardo(Vision Engineering (Italy)), Mauro Alaibac(University of Padua), Stefano Titli(University of Turin), Ugo Bottoni(Magna Graecia University), Piergiacomo Calzavara‐Pinton(University of Brescia), Serena Rupoli(Unknown), Paolo Fava, Michele Fimiani(University of Siena), Emilio Berti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), A.M. Mamusa, Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Angelo Carbone(Università Cattolica del Sacro Cuore), Nicola Pimpinelli(University of Florence), Maria Grazia Bernengo(University of Turin)
Cited by 130
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Defining early mycosis fungoides
|Journal of the American Academy of Dermatology|2005|543
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523